BELLICUM PHARMACEUTICALS, INC Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2018 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Bellicum Pharmaceuticals, Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2018 to Q3 2023.
  • Bellicum Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $116K, a 83.1% decline year-over-year.
  • Bellicum Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $1.45M, a 47.5% decline year-over-year.
  • Bellicum Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2022 was $2.61M, a 24.1% decline from 2021.
  • Bellicum Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2021 was $3.44M, a 31.6% decline from 2020.
  • Bellicum Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2020 was $5.03M, a 31.4% decline from 2019.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $1.45M $116K -$569K -83.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $2.02M $59K -$552K -90.3% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $2.57M $559K -$40K -6.68% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $2.61M $714K -$148K -17.2% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-31
Q3 2022 $2.76M $685K -$168K -19.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $2.93M $611K -$210K -25.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $3.14M $599K -$304K -33.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 $3.44M $862K +$324K +60.2% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 $3.12M $853K -$753K -46.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $3.87M $821K -$743K -47.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $4.61M $903K -$420K -31.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $5.03M $538K -$1.03M -65.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-24
Q3 2020 $6.07M $1.61M -$28K -1.71% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $6.09M $1.56M -$432K -21.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $6.53M $1.32M -$813K -38.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $7.34M $1.57M -$1.4M -47.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 $8.74M $1.63M -$2.04M -55.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $10.8M $2M -$1.58M -44.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 $12.4M $2.14M -$1.47M -40.7% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $13.8M $2.97M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $3.68M Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-06
Q2 2018 $3.57M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-05
Q1 2018 $3.61M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.